APIs for research and impurities

Fluticasone furoate impurity I is a drug product that is custom synthesized for research and development. It is an analytical standard that is used in metabolism studies. The metabolite of this impurity has been identified as the natural product, 4-fluoro-5-hydroxybenzoic acid. Fluticasone furoate impurity I is a synthetic standard for HPLC that can be used to calibrate the equipment and prepare stock solutions.

D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.

Tirzepatide impurity

D-Thr(5)-Semaglutide is a semaglutide impurity. The amino acid at position 5 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.

Tirzepatide impurity.

Tirzepatide impurity.

D-Glu(21)-Semaglutide is a semaglutide impurity. The amino acid at position 21 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.

Tirzepatide Impurity

D-Thr(7)-Semaglutide is a semaglutide impurity. The amino acid at position 7 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.

Tirzepatide impurity

D-Arg(30)-Semaglutide is a semaglutide impurity. The amino acid at position 30 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.

Tirzepatide Impurity

Cefpodoxime proxetil impurity H is an impurity of cefpodoxime proxetil, which is a prodrug that has been shown to be metabolized by esterases to the active form cefpodoxime. Cefpodoxime proxetil impurity H was found in the elution fraction when using liquid chromatography with reversed-phase as the separation method. It is thought that this impurity may arise from the use of methanol in the process of preparing cefpodoxime proxetil, although other mechanisms have not been ruled out. The mass spectrum for cefpodoxime proxetil impurity H shows peaks at m/z 812 and 682, which correspond to the parent drug and its hydrolysis product, respectively. The fragmentation pattern observed for cefpodoxime proxetil impurity H corresponds to that seen for cephalosporins.

2-Acetamido-9-[2-(acetyloxy)ethoxy]methyl-6,9-dihydro-1H-purin-6-one (ademetionine) is a prodrug that is metabolized in the liver to form ademetionine. Ademetionine is a potent inhibitor of guanosine deaminase, which is an enzyme that breaks down guanosine into guanine and ammonia. Ademetionine has shown efficacy in cancer treatment and may also be used to treat tuberculosis. The metabolism of this drug takes place in the liver, where it undergoes oxidation by cytochrome P450 enzymes to form the active metabolite ademetionine. Metabolism of this drug can be inhibited by drugs such as trifluoromethanesulfonic acid (TFMS), which are used for the treatment of malaria. TFMS inhibits the formation of ademetionine but does not affect the formation

Dihydro-alpha-ergocryptine mesylate is a drug that inhibits the effects of ergotamine and other drugs. It is used in animals to treat drug reactions, such as those caused by morphine and penicillin. Dihydro-alpha-ergocryptine mesylate can be detected in urine samples for up to 72 hours after administration. The pharmacokinetic properties of this drug are not well understood, but there is a linear relationship between dose and plasma concentration. The clinical response to dihydro-alpha-ergocryptine mesylate has been shown to be dose dependent. This drug also has dopaminergic properties, which may be due to its ability to bind with dopamine receptors in the central nervous system. There are several symptoms that may be related to taking this drug, including drowsiness or fatigue, nausea or vomiting, dry mouth, muscle spasms, and involuntary shaking of a part of the body (tremor).

5-Benzamidolevulinic acid is an ethylamine derivative that inhibits the enzyme carbonic anhydrase. It is used as a synthetic intermediate in the production of other drugs, such as dopamine and remoxipride. 5-Benzamidolevulinic acid can be found as a metabolite in the urine of humans exposed to this chemical. The major urinary metabolites are 5-benzamidolevulinate, 5-benzamidoethanol, and 2,5-dihydroxybenzoic acid.

Decitabine is a drug product that is used as an anti-cancer drug. It is a synthetic, natural, and research and development (R&D) metabolite with the CAS No. 909402-26-2. Decitabine has shown anticancer activity in vitro and in vivo against leukemia cells. This compound is an impurity of the API decitabine that is manufactured by a chemical synthesis process. The analytical impurities are 11 compounds that have been identified from the HPLC standard of this API. The metabolites of these compounds are also included in this standard. High purity decitabine should be obtained for pharmacopoeia studies and niche applications such as HPLC standards, pharmaceuticals, or research purposes.